Epigenic
Latest round
- Series B
Last raised
- Sep 2025
Total raised
- $92M
Investors
- 5
About Epigenic
Established in 2021 and based in Shanghai, China, EPI Genic operates as a biotechnology company committed to developing next-generation gene editing therapy by regulation of epigenetic genomes. The company is committed to using its epigenetic regulation technology to treat a wide range of diseases. Its proprietary technology platform is explored through artificial intelligence (AI) algorithms, which can obtain CRISPR-Cas components that regulate target genes or manipulate the expression of multiple genes simultaneously without altering the DNA sequence. Combined with the company's Lipid Nanoparticle (LNP) drug delivery system, the company's technology platform has been validated in in-vivo and in-vitro models of ocular, neurological, metabolic, and rare diseases to deliver drugs precisely and to target cells and tissues. It also has multiple pipeline product candidates in place covering metabolic, cardiovascular, viral hepatitis, ophthalmology and rare diseases. The company generates revenue from providing gene editing therapy solutions. It will be also used by the company to rapidly advance multiple preclinical projects and continuously build technology platforms.
Who invested in Epigenic
5 investors across 3 rounds
See all investors in Epigenic
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Epigenic
Who invested in Epigenic?
Epigenic has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Epigenic raised?
Epigenic has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Epigenic last raise money?
Epigenic's most recent round on record is a Series B, in Sep 2025.
What does Epigenic do?
Established in 2021 and based in Shanghai, China, EPI Genic operates as a biotechnology company committed to developing next-generation gene editing therapy by regulation of epigenetic genomes.
Where is Epigenic headquartered?
Epigenic is headquartered in Shanghai, China.
Which VCs invest in companies like Epigenic?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Epigenic's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Epigenic? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.